Skip to main content
Thursday, September 17, 2026
MAP Alert Press MAP ALERT PRESS Verify a URL
Live
'You can't trust anything' from Anthropic, OpenAI leaders, lawyer says‘Spider-Man: Brand New Day’ Hits No. 1 on All-Time Domestic Chart, Topping ‘Force Awakens’OpenAI chief says "we've entered a new phase" of AI capabilitiesAI "self-regulation is a joke," Pro-Human Assembly organizer saysAmazon increases minimum starting pay, adds new discount for employeesSenate Republican on Trump claim AI threat is 'hoax': 'Come on''You can't trust anything' from Anthropic, OpenAI leaders, lawyer says‘Spider-Man: Brand New Day’ Hits No. 1 on All-Time Domestic Chart, Topping ‘Force Awakens’OpenAI chief says "we've entered a new phase" of AI capabilitiesAI "self-regulation is a joke," Pro-Human Assembly organizer saysAmazon increases minimum starting pay, adds new discount for employeesSenate Republican on Trump claim AI threat is 'hoax': 'Come on'
Healthcare

STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal

By Andrew Joseph STAT News

MAP Verified Summary — reported by STAT News

AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.

This story’s context record documents 7 observable dimensions — Origin, Attribution, Specificity, Timing, Framing, Context Change, and Information Relationships — as part of Media Alert Press’s context-documentation ledger. MAP does not score or rate this content. Read the full original story at STAT News →

Discover more from Media Alert Press

Subscribe to get the latest posts sent to your email.

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.

Powered by